Juvenescence: Investing in the Age of Longevity
With their previous books published over the past 9 years, Mellon and Chalabi have established an excellent track record of recognising investment opportunities before they become mainstream, starting with forecasting the Great Recession in 2008, and identifying gold as an excellent hedge. More recently, they have written about life sciences, and their recommended stocks in Cracking the Code have outperformed every major market in the world. Equally their main stock picks in Fast Forward have yielded market busting returns.
They believe that to be successful, investors need to be curious, adaptable and apply themselves before they commit capital to an idea. For this new book, Jim and Al have spent a year sifting through the cutting-edge research, visiting laboratories and interviewing key opinion leaders in the field of life extension. They have written this up for the investor, stripping away the technical jargon and demystifying the information to help you to understand the science and clearly identify the key industry participants and investment opportunities.
They also discuss the personal benefits of a healthy life explaining what is good and what is bad for you and how current research indicates that making small changes can reap significant rewards which lead to longer, healthier lives.
By reducing the impact of diseases such as diabetes, osteoporosis through medical research and increasing healthy lifestyles, the risk of suffering in old age is significantly reduced.
Millions of people die from medical conditions caused by aging each year. Recent discoveries and anticipated near term developments in the understanding of the ageing process at the cellular and molecular level are going to be some of the most important contributors to repairing damaged cells and slowing or potentially reversing the root causes of ageing. Breakthroughs in gene editing techniques, stem cell therapies, immunotherapies and artificial intelligence all hold great promise.
Live longer, healthier and compress morbid state of sickness at
end of life into a few weeks.
Professor David Sinclair, Harvard Medical School